Immunization with mannosylated nanovaccines and inhibition of the immune-suppressing microenvironment sensitizes melanoma to immune checkpoint modulators

Antigens reversibly conjugated to a polymeric glyco-adjuvant induce protective humoral and cellular immunity

(2019) D. Scott Wilson et al.   NATURE MATERIALS

Eradication of spontaneous malignancy by local immunotherapy

(2018) Idit Sagiv-Barfi et al.   Science Translational Medicine

Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment

(2016) Andrew Stiff et al.   CANCER RESEARCH

Incipient Melanoma Brain Metastases Instigate Astrogliosis and Neuroinflammation

(2016) H. Schwartz et al.   CANCER RESEARCH

Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling

(2016) Andy J. Minn et al.   CELL

Rationale for anti-OX40 cancer immunotherapy

(2016) Sandrine Aspeslagh et al.   EUROPEAN JOURNAL OF CANCER

Targeted Delivery of Immunomodulators to Lymph Nodes

(2016) Jamil Azzi et al.   Cell Reports

Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy

(2016) Maarten Swart et al.   Frontiers in Oncology

Engineering Polymer Hydrogel Nanoparticles for Lymph Node-Targeted Delivery

(2015) Stefaan De Koker et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Towards a commercial process for the manufacture of genetically modified T cells for therapy

(2015) A D Kaiser et al.   CANCER GENE THERAPY

In vivo delivery of peptides and Toll-like receptor ligands by mannose-functionalized polymeric nanoparticles induces prophylactic and therapeutic anti-tumor immune responses in a melanoma model

(2015) Joana M. Silva et al.   JOURNAL OF CONTROLLED RELEASE

Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK

(2015) Idit Sagiv-Barfi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Next Hurdle in Cancer Immunotherapy: Overcoming the Non–T-Cell–Inflamed Tumor Microenvironment

(2015) Thomas F. Gajewski   SEMINARS IN ONCOLOGY

Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma

(2014) F. Stephen Hodi et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer

(2014) Zhiqiang Guo et al.   PLoS One

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment

(2014) Stefani Spranger et al.   Journal for ImmunoTherapy of Cancer

Development of PLGA-Mannosamine Nanoparticles as Oral Protein Carriers

(2013) Maria Alonso-Sande et al.   BIOMACROMOLECULES

Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab

(2013) Christiane Meyer et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells

(2013) Hongliang Fang et al.   Cellular & Molecular Immunology

A Randomized Phase II Trial of Multiepitope Vaccination with Melanoma Peptides for Cytotoxic T Cells and Helper T Cells for Patients with Metastatic Melanoma (E1602)

(2013) C. L. Slingluff et al.   CLINICAL CANCER RESEARCH

Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment

(2012) Douglas Hanahan et al.   CANCER CELL

Blockade of Myeloid-Derived Suppressor Cells after Induction of Lymphopenia Improves Adoptive T Cell Therapy in a Murine Model of Melanoma

(2012) K. N. Kodumudi et al.   JOURNAL OF IMMUNOLOGY

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

(2012) Alfons JM van den Eertwegh et al.   LANCET ONCOLOGY

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dynamic light scattering as an efficient tool to study glyconanoparticle–lectin interactions

(2011) Xin Wang et al.   ANALYST

The pro- and anti-inflammatory properties of the cytokine interleukin-6

(2011) Jürgen Scheller et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice

(2010) Qing Zhu et al.   JOURNAL OF CLINICAL INVESTIGATION

Mechanism of T Cell Tolerance Induced by Myeloid-Derived Suppressor Cells

(2010) S. Nagaraj et al.   JOURNAL OF IMMUNOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Brain Metastasis: Opportunities in Basic and Translational Research

(2009) E. A. Maher et al.   CANCER RESEARCH

CCL2 Blockade Augments Cancer Immunotherapy

(2009) Z. G. Fridlender et al.   CANCER RESEARCH

OX40 (CD134) expression in sentinel lymph nodes correlates with prognostic features of primary melanomas

(2008) MaryClare Sarff et al.   AMERICAN JOURNAL OF SURGERY

C-type lectins on dendritic cells: key modulators for the induction of immune responses

(2008) Yvette van Kooyk   BIOCHEMICAL SOCIETY TRANSACTIONS